Corante

About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
MedChem Buzz
Kilomentor
On Pharma
A New Merck, Reviewed
Liberal Arts Chemistry
One in Ten Thousand
Electron Pusher
Periodic Tabloid
All Things Metathesis
C&E News Blog
Propter Doc
Chemiotics II
The Chemical Notebook
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
Chirality
BBSRC/Douglas Kell
ChemBark
Drug Discovery Opinion
Realizations in Biostatistics
Chemjobber
Pharmalot
WSJ Health Blog
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Useful Chemistry
Chiral Jones
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Totally Synthetic
Fragment Literature
The F- Blog
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Carbon-Based Curiosities
Experimental Error
Business|Bytes|Genes|Molecules
Eye on FDA
Sigma-Aldrich ChemBlogs
Chemical Forums
Depth-First
Symyx Blog
P212121
ChemCafe
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
A Scientist's Life
Speculist
Cosmic Variance
The Capsule
Zeroth Order Approximation
Biology News Net


Medical Blogs
Med Tech Sentinel
DB's Medical Rants
Science-Based Medicine
GruntDoc
The Health Care Blog
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Megan McArdle
Mickey Kaus
Colby Cosh
Alien Corn
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Waiting for the FDA | Main | Can Med-Chem Help With Bird Flu? »

February 20, 2005

COX-2 Aftermath

Email This Entry

Posted by Derek

Overall, I found the conclusionsn of the FDA's COX-2 committee quite reasonable (and not too far from what I predicted during the day on Friday.) Perhaps their actions will calm things down a bit. After all, they had the chance to bay at the moon, yank everything off the market and call for heads on pikes. But they ended up saying (I'm paraphrasing just a bit): "Y'know, these drugs really do have side effects. But a lot of stuff does. And they do some people some good. Maybe if just the people who really need them take them, things will work themselves out."

This all should make Merck's path forward in their Vioxx lawsuits a little easier. They could still face a punitive-damages avalanche, of course, and a lot of lawyers will be working to get the snowpack loosened up. I assume that the first case will be tried in Mississippi, Texas, or some other jury award paradise - picking the right venue is part of the art.

I'm just glad that the "Toxic drugs! Film at eleven!" momentum has been lost. I think that the industry, the stock market, the public, and (most definitely) the press were really close to panic there for a bit. (Naturally enough, in the last case, since panic sells.) But outside of advertising revenue, it does no one any good. If you make the right decision in that frame of mind, it's generally by accident.

Comments (2) + TrackBacks (0) | Category: Cardiovascular Disease


COMMENTS

1. John Thacker on February 21, 2005 1:27 PM writes...

"I assume that the first case will be tried in Mississippi, Texas, or some other jury award paradise - picking the right venue is part of the art."

Possibly not. The recently passed and signed Class Action Fairness Act curtails venue shopping by quite a lot. Basically it removes to federal court class action lawsuits which consist of people in several states suing over behavior in several states. No longer can people forum shop by having one named member of the class being from the named state.

Permalink to Comment

2. John Wurzelmann on February 22, 2005 10:44 AM writes...

In a somewhat related aside, Why is it that the public or industry professionals have to pay for electronic access to advisory meetings such as just took place? It seems to me at the least that an audio feed, either live streaming or off-line format (MP3) should be available at the FDA or elsewhere. After all the FDA is supported by Tax payer money. Let's hear it for transparency in government. Perhaps the blogosphere, with its legendary political clout, can start a groundswell of enthusiasm for democratic reform of this public forum. I know transcripts will eventually be available, but I'd rather listen at my computer while otherwise multi-tasking.

John W

Permalink to Comment


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Academia and Industry, Suing Each Other
Let's Start Off the Meeting With An Ad, OK?
The Academic-Industrial Collaboration in Drug Discovery Panel: Today
Glass Structure, Atom by Atom
How the Andrulis Paper Got Published
AstraZeneca in Waltham
Fluorine NMR: Why Not?
AstraZeneca Layoffs and Closings